Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics Rises 37% in First Hong Kong Trading Session

publication date: Jun 13, 2017
In its first day of trading on the Hong Kong Exchange, WuXi Biologics rose 37%, showing that the newly listed company continues to attract heavy investor following its IPO. The open market trading increased the company's market capitalization to $4.1 billion. Last week, WuXi Biologics raised $511 million in an IPO that was heavily oversubscribed. The company comprises the biologic CRO/CMO operations of well-known WuXi AppTec, which continues to be privately held. Headquartered in Wuxi city, Wuxi Biologics has facilities in Wuxi, Shanghai and Suzhou. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital